stimulating factor (GM-CSF) significantly enhanced IFN-\(\lambda\)/3 production by 2–5 fold. In pDC-NK cell co-cultures from SLE patients, IFN-\(\alpha\)/2b and GM-CSF increased the proportion of RNA-IC responding IFN-\(\lambda\)/3 producing individuals from 9% to 36%. Hydroxychlooroquine as well as an interleukin receptor 1 associated kinase 4 inhibitor (IRAK4i) significantly inhibited the RNA-IC-triggered IFN-\(\lambda\)/3 production by pDCs and pDC-NK cell co-cultures by >90%.

Conclusions Type III IFN production in a small subset of pDCs can be triggered by RNA containing IC, enhanced by NK cells and several pro-inflammatory cytokines, and inhibited by blocking the TLR-MyD88 pathway, resembling the regulation of type I IFN. Thus, our results support a contributing role for both type I and type III IFN in SLE, which needs to be considered when targeting the IFN system in this disease.

---

**Deficiency of Marginal-Zone B Cells in Peripheral Blood of SLE Patients in Clinical Remission or Low Disease Activity State in a Long-Term Study**

1. Zbynek Hrnčir, 2Doris Vokurková, 3Marcela Drahosová, 4Tomas Soukup. 2nd Dept. of Internal Medicine, University Hospital, Hradec Králové, 3Dept. of Immunology and Allergy, University Hospital, Hradec Králové, Czech Republic.

10.1136/lupus-2020-eurolupus.141

**Purpose** Deficiency of marginal-zone B cells was observed in peripheral blood (PB) of SLE pts in clinical remission or low disease activity (LDA)1. Goal of the prospective, comparative, long-term study is follow-up of this phenomenon.

**Methods** Forty five adult SLE (ACR/1982, updated 1997) pts in complete remission or LDA2 and 10 age- and sex-matched healthy controls (HC) were enrolled in „month 0”, and SLE also after twelve-months („month 12”) and 36-months („month 36”) period; overlap syndromes, infection, renal failure and monoclonal gammapathy in SLE were excluded. The DuraClone IM panel (Beckman Coulter) was used to identify CD19+CD27+IgM+ B cell subpopulation in PB samples by flow cytometry navios (Beckman Coulter) with software analysis using Kaluza version 1.2.; data obtained were expressed in relative% of PB lymphocytes and absolute values x10⁶/L, and processed using Medcalc-Statistical Software programme.

**Results** Significant differences (p =0.002 - <0.001) were obtained between absolute values of CD19+CD27+IgM+ B cells in HC (median 31.36, 95% CI 21.49 – 63.35) and SLE „month 0” (median 13.17, 95% CI 7.87 – 17.09), SLE „month 12” (median 10.36, 95% CI 7.24 – 16.04), and SLE „month 36” (median 9.66, 95% CI 7.22 – 13.21), but not between values obtained in SLE „month 0”, „month 12” and „month 36” (p>0.05); not significant differences were found using analysis according to relative% of B cells under study (p>0.05).

**Conclusion** Data obtained demonstrated a long-term deficiency of marginal-zone B cells in PB of SLE pts in complete remission or LDA; susceptibility to infection should be supposed, but further studies are necessary.

**Acknowledgement** Research project PROGRES Q40-15, Charles Univ. Faculty of Medicine, Hradec Králové, Czech Republic.

---

**References**


---

**Neutrophils in LUPUS: A NEW PHENOTYPE**

1Sandrine Huot, 2Cynthia Lalafarme, 3Martin Pelletier, 4Philippe Tessier, 5Eric Boillard, 6Paul B Fortin, 7Marc Pouliot. 2Dept. of Microbiology and Immunology, Université Laval, Québec, Canada; 3Dept. of Medicine, Université Laval, Québec, Canada.

10.1136/lupus-2020-eurolupus.142

**Background** Polymorphonuclear neutrophils (PMNs) with irregular properties have been reported in patients with lupus and compelling evidence implicates them as a source of self-antigens. PMNs are the most abundant circulating leukocytes in human blood; defining their implication either as inherently defective players or as cells affected by external factors (e.g. autoantibodies, immune complexes and type I interferon) is of interest. We propose that elements present in the blood of patients with lupus affect neutrophil function/viability, in a NETosis-independent fashion.

**Methods** PMNs were isolated from venous blood of healthy volunteers and incubated with serum from normal subjects or from patients with lupus. Apoptosis and necrosis were assessed in real-time by cell surface exposure of phosphatidylserine (PS) and loss of plasma membrane integrity, respectively. Serums’ analytes measurements were made by LumineX and ELISA.

**Results** Serums from patients with lupus caused a transient increase in PS exposure on the outer leaflet of PMN plasma membrane, in a significantly more intense fashion than serums from normal individuals. This peculiar phenomenon, which does not have characteristics of classic apoptosis, correlated with the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), in contrast to any of the following serum analytes: cytokines, chemokines, circulating growth factors, HMGB1, S100A8 and A9 proteins, complement components C3 and C4, immunoglobulins (IgA, IgG, IgM) and leukocyte counts. However, the transient PS increase was abolished by the decocomplementation of the sera or by blocking the Fc receptors on PMNs’ surface.

**Conclusions** Healthy PMNs are affected by the serum of patients with lupus. The transient PS exposure on the outer leaflet of the cellular membrane constitutes a new phenotype directly linked with factors that are at play in the blood of patients. Ongoing studies are looking at the nature of this new phenotype and how it links with PMNs being a potential source of self-antigens and/or as players unduly activated in lupus.

---

**Effectors DN2 B Cells Are Expanded in A Mixed Ancestry Colombian SLE Patient Population**

1Carolina Hurtado, 2Diego Rojas-Gualdron, 3Ricardo Pineda, 4Scott Jenkins, 5Gloria Vasquez, 4Frisaki Sanz. 1School of Graduate Studies and School of Medicine, CES University, Medellín, Colombia; 2School of Medicine, CES University, Medellín, Colombia; 3Group of Clinical Information, Arrollabca IPS, Medellín, Colombia; 4Dept. of Medicine, Division of Rheumatology, Lowance Center for Human Immunology, Emory University, Atlanta, USA; 5Grupo de inmunología celular e inmunogenética, Universidad de Antioquia, Medellín, Colombia.

10.1136/lupus-2020-eurolupus.143

**Background** Double Negative (DN) B lymphocytes are expanded in Systemic Lupus Erythematosus (SLE). Specifically, DN2 cells are a DN subset recently characterized and are functionally plasmablasts precursors. DN2 frequency is higher in SLE patients of African American ancestry and is associated